SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is seeing intense market activity as investors speculate on its real-world integration into the live music industry and potential future partnerships. The community remains divided, with many celebrating the token's rapid growth and unique cultural ownership model, while others debate whether the current momentum is sustainable or purely speculative.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining momentum as market participants debate its identity as a satirical homage to Bitcoin versus its potential as a serious asset, fueled by ongoing community lore and claims of major whale interest. Supporters are actively pushing the project as the next big meme narrative, while critics remain skeptical of the project's long-term utility.

Maulcoin

Maulcoin is trending as its community of 'Maulers' aggressively pushes for organic growth, focusing on holding through volatility and aiming to erase zeros from its price. Investors are actively coordinating social media engagement and awaiting a potential breakout fueled by consistent community conviction and long-term diamond-hand strategies.

Codatta

Codatta (XNY) is seeing intense community engagement as traders speculate on its AI-driven data utility and technical recovery patterns following recent volatility. The conversation is currently dominated by debates over whether the token is undergoing a genuine bullish breakout fueled by upcoming on-chain fingerprint verification or if it is susceptible to pump-and-dump mechanics.

Amplify ETF Trust - Amplify CPW Enhanced Dividend Income ETF

Amplify CPW Enhanced Dividend Income ETF

DIVO is gaining attention among income-focused investors who value a balanced approach that combines monthly cash flow from dividend-paying blue-chip stocks with the capital appreciation potential of an actively managed covered call strategy. Community members frequently discuss the ETF as a "sleep-well-at-night" holding, often grouping it with other popular income strategies like JEPI, SCHD, and SPYI to build portfolios that prioritize stability and long-term capital preservation over chasing volatile high-yield plays.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to the company's critical role as a monopoly in the semiconductor supply chain, with community discussion centered on its massive EUV backlog and its status as an indispensable 'picks-and-shovels' play for the ongoing AI infrastructure buildout. Traders are actively debating whether to capitalize on recent dips, noting the stock's long-term strength while remaining cautious about volatility stemming from broader semiconductor sector rotations and geopolitical supply chain risks.

The 401jK (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and the popular US based 401(k) retirement plan and other pension plans around the world  Through the meme fueled humor, irony, satire &amp; inspiration from cypherpunk ideology, real life data, and current events... the 401jK community aims to comment on the fact that global markets are heavily manipulated for selfish purposes by the same people who control these pension funds... while also aiming to twist the heads of the 401k and global pension systems.  It is a retirement plan that seeks to make social, political, economic commentary fueled by the memes and dreams of the hive mind of the community that makes up 401jK  The rules have changed, and the game was always rigged.  It's time to wake up, adapt, rebel, and heal.  Welcome to 401jK

401jK

The 401JK community is actively rallying behind the narrative of "Resisting and Retiring" to challenge traditional financial systems, with sentiment fueled by grassroots IRL raids, educational initiatives, and a steady stream of memes. Investors are currently debating the project's long-term viability, weighing its dedicated community-led growth and roadmap against broader market volatility and skeptical claims of it being a pump-and-dump scheme.

Monero

Monero is trending as the community doubles down on the asset's utility as a private, quantum-resistant store of value amid increasing regulatory scrutiny. Supporters are actively discussing its role as a hedge against surveillance while comparing it to other privacy coins in a volatile market.

Grok's first token launched on Base, deployed directly on X with help of Bankr. Proof of deployment here, https://x.com/grok/status/1897949874961650169.  Join the DRB community if this story intrigues you, follow it as it unfolds into this new AI era.  Grok earns swap fees - Grok's trading wallet: 0xb1058c959987e3513600eb5b4fd82aeee2a0e4f9.  Articles, media coverages on $DRB featured here, https://linktr.ee/DRBtaskforce.  Our dev, is grok, one of the front-running candidate to achieve AGI.

DebtReliefBot

DebtReliefBot is trending as investors rally around its perceived connection to Grok and Elon Musk, fueling community speculation about potential AI-driven growth. Market participants are actively discussing the token's early-stage potential on the Base network, often highlighting its integration with the broader Bankr ecosystem.

Ethena

Ethena (ENA) is trending as investors focus on massive institutional capital inflows and treasury strategies involving StablecoinX, which are fueling community speculation about its role in the next generation of finance. The community is actively discussing key leadership connections, upcoming SEC filing deadlines, and the potential for a major price breakout as the project expands its ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit...

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC ImmunityBio, Inc. Securities Fraud Class...

IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results

ImmunityBio stock jumps 7% as Q1 2026 revenues surge 168% on strong Anktiva uptake, with expanding approvals and pipeline progress boosting momentum.

IBRX INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ImmunityBio, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ImmunityBio, Inc. (NASDAQ: IBRX) publicly traded securities between January 19, 2026 and March 24, 2026, inclusive (the...

IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026

IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 IBRX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ImmunityBio...

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman

ImmunityBio, Inc. (IBRX) Facing Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman ImmunityBio, Inc...

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP

ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP ImmunityBio, Inc. (IBRX) Investors: May 26, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP PR Newswire...

ImmunityBio (NASDAQ:IBRX) Trading Up 7.1% - Still a Buy?

ImmunityBio (NASDAQ:IBRX) Trading Up 7.1% - Here's What Happened...

Why Is ImmunityBio Stock Rallying Thursday?

ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning prompts review of promotional claims.read more...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming Deadlines - IBRX INVESTOR ALERT: Pomerantz Law Firm...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Warranted - fundamentals justify the decline

Overdone - the market is overreacting

Too early to tell

Is the selloff in software stocks warranted or overdone?

Stocktwits

Stocktwits Polls

Retail investors are piling in to challenge the massive short interest and predatory market maker tactics pinning the price.

Expectations are high for an upcoming appearance on the Sean Spicer show, which bulls hope will provide a catalyst and public exposure.

Bullish sentiment is building around a massive 168% year-over-year jump in preliminary quarterly revenue to $44.2 million.

Frustrated traders are blaming weekly options expiration and market maker manipulation for the stock's predictable downward pressure.

The ongoing battle with the FDA over regulatory warnings and restricted drug claims has fueled intense skepticism toward the agency.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest IBRX News

IBRXImmunityBio Inc